Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib

Adverse events are anticipated during a clinical development program. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We describe here the process undertaken by Pfizer to investigate a safety signal for pancreatic cancer with tofacitinib. Potential cases...

Descripción completa

Detalles Bibliográficos
Autores principales: Dasic, Gorana, Jones, Thomas, Frajzyngier, Vera, Rojo, Ricardo, Madsen, Ann, Valdez, Hernan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817838/
https://www.ncbi.nlm.nih.gov/pubmed/29417755
http://dx.doi.org/10.1002/prp2.371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817838/
https://www.ncbi.nlm.nih.gov/pubmed/29417755
http://dx.doi.org/10.1002/prp2.371

Ejemplares similares